| Literature DB >> 31341478 |
Frank Mayta-Tovalino1,2, Yens Mendoza-Martiarena2, Percy Romero-Tapia2, María Álvarez-Paucar2, Luis Gálvez-Calla2, Juan Calderón-Sánchez3, Rodolfo Bolaños-Cardenas4, Antonio Diaz-Sarabia1.
Abstract
AIM: To analyze the risk factors by logistic regression and perform the analysis of the survival rate of osseointegrated dental implants placed in public and private institutions.Entities:
Year: 2019 PMID: 31341478 PMCID: PMC6612967 DOI: 10.1155/2019/3527872
Source DB: PubMed Journal: Int J Dent ISSN: 1687-8728
General risk factors of osseointegrated dental implants.
| Public and private institutions | |||||||
|---|---|---|---|---|---|---|---|
| Factors | Category | UPCH-SI, | HCFAP, | CMNAVAL, | UPSJB, | UPCH-SM, | Total, |
| Sex (X1) | Female | 50 (22.9) | 15 (6.8) | 29 (13.3) | 13 (5.9) | 111 (50.9) | 218 (100) |
| Male | 17 (7.9) | 26 (12.2) | 114 (53.5) | 16 (7.5) | 40 (18.7) | 213 (100) | |
|
| |||||||
| Location (X2) | Jaw | 27 (13.1) | 21 (10.19) | 77 (37.3) | 15 (7.2) | 66 (32.0) | 216 (100) |
| Maxilla | 40 (17.7) | 20 (8.8) | 66 (29.3) | 14 (6.2) | 85 (37.7) | 225 (100) | |
|
| |||||||
| Hypertension (X3) | Not present | 53 (14.6) | 28 (7.7) | 124 (34.1) | 23 (6.3) | 135 (37.1) | 363 (100) |
| Present | 14 (20.5) | 13 (19.1) | 19 (27.9) | 6 (8.8) | 16 (23.5) | 68 (100) | |
|
| |||||||
| Antibiotic therapy (X4) | Not present | 0 | 0 | 0 | 0 | 0 | 0 |
| Present | 67 (15.5) | 41 (9.5) | 143 (33.1) | 29 (6.7) | 151 (35.0) | 431 (100) | |
|
| |||||||
| Diabetes (X5) | Not present | 67 (15.9) | 41 (9.7) | 138 (32.7) | 27 (6.4) | 148 (35.1) | 421 (100) |
| Present | 0 | 0 | 5 (50) | 2 (20) | 3 (20) | 10 (100) | |
|
| |||||||
| Osteoporosis (X6) | Not present | 57 (13.6) | 40 (9.5) | 143 (34.1) | 29 (6.9) | 150 (35.8) | 419 (100) |
| Present | 10 (83.3) | 1 (8.3) | 0 | 0 | 1 (8.3) | 12 (100) | |
|
| |||||||
| Bisphosphonates (X7) | Not present | 62 (14.5) | 41 (9.6) | 143 (33.5) | 29 (6.8) | 151 (35.4) | 426 (100) |
| Present | 5 (100) | 0 | 0 | 0 | 0 | 5 (100) | |
|
| |||||||
| History of periodontitis (X8) | Not present | 63 (19.8) | 21 (6.6) | 94 (29.5) | 17 (5.2) | 123 (38.6) | 318 (100) |
| Present | 4 (3.5) | 20 (17.7) | 49 (43.3) | 12 (10.6) | 28 (24.7) | 113 (100) | |
|
| |||||||
| Hypercholesterolemia (X9) | Not present | 67 (17.2) | 40 (10.2) | 122 (31.3) | 23 (5.9) | 137 (35.2) | 369 (100) |
| Present | 0 | 1 (2.3) | 21 (50) | 6 (14.2) | 14 (33.3) | 42 (100) | |
UPCH-SI: Universidad Peruana Cayetano Heredia, San Isidro; HCFAP: Hospital Central de la Fuerza Aérea del Perú; CMNAVAL: Centro Medico Naval; UPSJB: Universidad Privada San Juan Bautista; UPCH-SM: Universidad Peruana Cayetano Heredia, San Martin de Porres.
Surgical risk factors of osseointegrated dental implants.
| Factors | Category | UPCH-SI, | HCFAP, | CMNAVAL, | UPSJB, | UPCH-SM, | Total, |
|---|---|---|---|---|---|---|---|
| Bone quality (X10) | Type I | 2 (7.4) | 0 | 7 (25.9) | 1 (3.7) | 17 (62.9) | 27 (100) |
| Type II | 36 (10.4) | 32 (9.8) | 119 (34.4) | 26 (7.5) | 132 (38.2) | 345 (100) | |
| Type III | 28 (49.1) | 9 (15.7) | 17 (29.8) | 2 (3.5) | 1 (1.7) | 57 (100) | |
| Type IV | 1 (50) | 0 | 0 | 0 | 1 (50) | 2 (100) | |
|
| |||||||
| Bone quantity (X11) | A | 0 | 1 (4.5) | 6 (27.2) | 1 (4.5) | 14 (63.6) | 22 (100) |
| B | 47 (19.3) | 33 (13.5) | 68 (27.9) | 13 (5.3) | 82 (33.7) | 243 (100) | |
| C | 18 (12.1) | 7 (4.7) | 69 (46.6) | 14 (9.4) | 40 (27.0) | 148 (100) | |
|
| |||||||
| Design (X12) | Conical | 6 (7.32) | 0 | 38 (46.3) | 27 (32.9) | 11 (13.4) | 82 (100) |
| Cylindrical | 20 (29.8) | 14 (20.9) | 16 (23.8) | 0 | 17 (25.3) | 67 (100) | |
| Hybrid | 41 (14.5) | 27 (9.5) | 89 (31.5) | 2 (0.7) | 123 (43.6) | 282 (100) | |
|
| |||||||
| Smoker (X13) | Not present | 60 (14.1) | 41 (9.6) | 143 (33.7) | 29 (6.8) | 151 (35.6) | 424 (100) |
| Present | 7 (100) | 0 | 0 | 0 | 0 | 7 (100) | |
|
| |||||||
| Connection (X14) | Internal | 7 (3.2) | 40 (18.6) | 130 (60.4) | 3 (1.4) | 35 (16.2) | 215 (100) |
| External | 6 (85.7) | 0 | 18 (14.2) | 0 | 0 | 7 (100) | |
| Morse cone | 54 (25.8) | 1 (0.4) | 12 (5.7) | 26 (12.4) | 116 (55.5) | 209 (100) | |
|
| |||||||
| Type of edentulism (X15) | Total | 3 (21.4) | 0 | 0 | 0 | 11 (78.5) | 14 (100) |
| Partial | 64 (15.3) | 41 (9.8) | 143 (34.2) | 29 (6.9) | 140 (33.5) | 417 (100) | |
|
| |||||||
| Staging (X16) | First stage | 1 (9.0) | 0 | 3 (27.2) | 6 (54.5) | 1 (9.0) | 11 (100) |
| Second stage | 66 (15.7) | 41 (9.7) | 140 (33.3) | 23 (5.4) | 150 (35.7) | 420 (100) | |
|
| |||||||
| 3D surgery (X17) | Not present | 67 (15.5) | 41 (9.5) | 143 (33.1) | 29 (6.7) | 151 (35.0) | 431 (100) |
| Present | 0 | 0 | 0 | 0 | 0 | 0 | |
|
| |||||||
| Load (X18) | Early | 0 | 0 | 7 (41.1) | 6 (35.2) | 4 (23.5) | 17 (100) |
| Conventional | 67 (16.1) | 41 (9.9) | 136 (32.8) | 23 (5.5) | 147 (35.5) | 414 (100) | |
|
| |||||||
| Bone graft (X19) | Not present | 59 (19.2) | 35 (11.4) | 95 (31.0) | 14 (4.5) | 103 (33.6) | 306 (100) |
| Present | 86 (6.4) | 6 (4.8) | 48 (38.4) | 15 (12.0) | 48 (38.4) | 125 (100) | |
|
| |||||||
| Peri-implantitis (X20) | Not present | 59 (14.4) | 40 (9.8) | 134 (32.8) | 27 (6.6) | 148 (36.2) | 408 (100) |
| Present | 8 (34.7) | 1 (4.3) | 9 (39.1) | 2 (8.7) | 3 (13.0) | 23 (100) | |
|
| |||||||
| Mucositis (X21) | Not present | 58 (14.2) | 40 (9.8) | 135 (33.0) | 27 (6.6) | 146 (36.2) | 408 (100) |
| Present | 9 (39.1) | 1 (4.3) | 8 (34.7) | 2 (8.7) | 3 (13.0) | 23 (100) | |
|
| |||||||
| GBR (X22) | Not present | 51 (16.7) | 34 (11.1) | 97 (31.6) | 16 (5.2) | 107 (35.0) | 305 (100) |
| Present | 16 (12.7) | 7 (5.5) | 46 (36.5) | 13 (10.3) | 44 (34.9) | 126 (100) | |
Multivariate logistic regression model of each risk factor on the success and survival of osseointegrated implants.
| Independent variables | OR |
| 95% CI |
|---|---|---|---|
| Age (X0) | 1.0 | 0.122 | 0.98–1.10 |
| Sex (X1) | 0.9 | 0.879 | 0.23–3.48 |
| Location (X2) | 0.5 | 0.312 | 0.13–1.88 |
| Hypertension (X3) | 0.5 | 0.463 | 0.11–2.72 |
| Antibiotic therapy (X4) | — | — | — |
| Diabetes (X5) | 5.6 | 0.167 | 0.48–65.9 |
| Osteoporosis (X6) | 44.8 | 0.011 | 2.40–834.8 |
| Bisphosphonates (X7) | 0.09 | 0.205 | 0.00–3.65 |
| History of periodontitis (X8) | 3.1 | 0.082 | 0.86–11.31 |
| Hypercholesterolemia (X9) | 5.1 | 0.046 | 1.02–25.44 |
| Bone quality (X10) | 5.8 | 0.021 | 1.30–26.6 |
| Bone quantity (X11) | 0.5 | 0.268 | 0.15–1.69 |
| Design (X12) | 1.5 | 0.388 | 0.57–4.16 |
| Smoker (X13) | 1.6 | 0.798 | 0.04–60.4 |
| Connection (X14) | 0.4 | 0.038 | 0.22–0.95 |
| Type of edentulism (X15) | 0.4 | 0.527 | 0.03–5.26 |
| Staging (X16) | — | — | — |
| 3D surgery (X17) | — | — | — |
| Load (X18) | — | — | — |
| Bone graft (X19) | 0.1 | 0.183 | 0.01–2.16 |
| GBR (X22) | 24.1 | 0.007 | 2.34–249.6 |
| Follow-up (X23) | 1.7 | 0.000 | 1.35–2.31 |
| Number of implants (X24) | 1.1 | 0.290 | 0.90–1.39 |
OR: odds ratio; CI: confidence interval; GBR: guided bone regeneration. Logit model: all the variables were entered in the statistical analysis of the multivariate model. The logit model showed that age, sex, location of the implant, antibiotic therapy, diabetes, bisphosphonates, history of periodontitis, bone quantity, implant design, smoking habit, type of edentulism, bone graft, and number of implants placed were not factors of statistically significant risk in the general logistic model for the failure of the implants (p < 0.05).
Rate of failure of osseointegrated implants in eleven years.
| Implants | Lost | Failure rate (%) | 95% CI | |
|---|---|---|---|---|
| Failure | 1279 | 23 | 17.98 | 11.95–27.06 |
Evaluation of the cumulative survival in 11 years of osseointegrated implants.
| Time (years) | Implants | Failure | Survival rate (%) | 95% CI |
|---|---|---|---|---|
| 1-2 | 431 | 2 | 99.4 | 97.8–99.8 |
| 2-3 | 320 | 3 | 98.3 | 96.0–99.3 |
| 3-4 | 217 | 5 | 95.4 | 91.5–97.6 |
| 4-5 | 117 | 2 | 93.6 | 88.5–96.4 |
| 5-6 | 88 | 5 | 87.0 | 78.6–92.2 |
| 6-7 | 49 | 4 | 78.9 | 67.2–86.8 |
| 7-8 | 33 | 1 | 75.7 | 62.5–84.8 |
| 8-9 | 16 | 0 | 75.7 | 62.5–84.8 |
| 9-10 | 5 | 0 | 75.7 | 62.5–84.8 |
| 10-11 | 2 | 1 | 37.8 | 1.6–79.3 |
| 11-12 | 1 | 0 | 37.8 | 1.6–79.3 |
The Kaplan–Meier method is used to determine the survival rate of the implant. The analysis was performed on 1279 osseointegrated implants during 11 years of functionality.
Distribution of implant survival by headquarters.
| Institution | Time (years) | Implants | Failure | Survival rate (%) | 95% CI |
|---|---|---|---|---|---|
| UPCH-SI | 1 | 67 | 0 | 100 | — |
| 2 | 56 | 1 | 98.2 | 87.9–99.7 | |
| 3 | 40 | 1 | 95.7 | 83.8–98.9 | |
| 4 | 23 | 1 | 91.6 | 74.4–97.4 | |
| 5 | 19 | 3 | 77.1 | 54.3–89.5 | |
| 6 | 6 | 2 | 51.4 | 19.0–76.5 | |
|
| |||||
| HCFAP | 1 | 41 | 0 | 100 | — |
| 2 | 14 | 0 | 100 | — | |
| 3 | 7 | 0 | 100 | — | |
| 4 | 4 | 0 | 100 | — | |
| 6 | 1 | 1 | 0.00 | — | |
|
| |||||
| CMNAVAL | 1 | 143 | 1 | 99.3 | 95.1–99.9 |
| 2 | 93 | 1 | 98.2 | 92.9–99.57 | |
| 3 | 62 | 4 | 91.9 | 82.3–96.3 | |
| 4 | 4 | 0 | 91.9 | 82.3–96.3 | |
| 5 | 3 | 1 | 61.2 | 82.3–96.3 | |
| 7 | 2 | 1 | 30.6 | 80.0–90.9 | |
| 10 | 1 | 1 | 0.00 | 1.0–73.6 | |
|
| |||||
| UPSJB | 1 | 29 | 1 | 96.5 | 77.9–99.5 |
| 2 | 14 | 1 | 89.6 | 62.1–97.5 | |
| 3 | 4 | 0 | 89.6 | 62.1–97.5 | |
| 7 | 1 | 0 | 89.6 | 62.1–97.5 | |
|
| |||||
| UPCH-SM | 1 | 151 | 0 | 100 | — |
| 2 | 143 | 0 | 100 | — | |
| 3 | 104 | 0 | 100 | — | |
| 4 | 85 | 1 | 98.8 | 91.9–99.8 | |
| 5 | 64 | 1 | 97.2 | 89.0–99.3 | |
| 6 | 39 | 1 | 94.7 | 83.8–98.3 | |
| 7 | 30 | 0 | 94.7 | 83.8–98.3 | |
| 8 | 15 | 0 | 94.7 | 83.8–98.3 | |
| 9 | 4 | 0 | 94.7 | 83.8–98.3 | |
| 11 | 1 | 0 | 94.7 | 83.8–98.3 | |
Figure 1Survival rate according to the time for the five institutions.